VAIM Expands JUVELOOK Production Capacity with New Headquarters and Manufacturing Facility

VAIM Expands JUVELOOK Production Capacity with New Headquarters and Manufacturing Facility

October 14, 2025 – VAIM, a leading medical aesthetics company, announced the completion of its new headquarters and state-of-the-art manufacturing facility. With this expansion, VAIM has significantly increased the production capacity of JUVELOOK, enhancing both supply stability and operational efficiency.

JUVELOOK is a patented collagen biostimulator formulated with a unique reticular porous complex structure that promotes natural collagen regeneration. To meet rising global demand, VAIM began operating its second manufacturing site in early September, located in Daejeon. The new facility is expected to triple the company’s total production capacity compared to previous levels.

Equipped with advanced automation systems, the new plant enhances both product quality and production safety. VAIM has also upgraded its in-house quality management system to strengthen consistency and reliability across its product portfolio. The company’s expanded R&D center within the new facility will focus on developing innovative products and exploring new opportunities in regenerative aesthetics.

Amid the rapid global growth of the medical aesthetics industry fueled by the K-beauty trend, VAIM recently launched JUVELOOK i and JUVELOOK G and hosted a successful clinical symposium on September 13, attended by over 500 doctors from across Korea.

A VAIM spokesperson stated, “Through continuous innovation and expansion, VAIM aims to solidify its position as a global leader in collagen biostimulators and medical aesthetics solutions.”

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM currently has product export contracts with 72 countries.